Mucolipidosis II (ML II) and Mucolipidosis III (ML III) represent different forms of the same underlying disorder. Both are caused by a deficiency in an enzyme responsible for directing important cellular enzymes to their proper location. Individuals with more severe symptoms are diagnosed with ML II, while those with milder or more slowly progressing symptoms are diagnosed with ML III.

​

Currently, treatment focuses on managing symptoms and improving quality of life, as there is no cure for the underlying condition. Researchers have explored several experimental approaches aimed at replacing the missing enzyme; however, no therapy has yet demonstrated significant long-term benefit.

​

ML II and ML III are extremely rare disorders and can sometimes be misdiagnosed, making it difficult to determine precise prevalence rates. Current estimates suggest that approximately two to three individuals per one million births are diagnosed with ML II or ML III.

​

The body continuously breaks down and recycles used materials within structures inside cells called lysosomes. Specialized enzymes carry out this process, but they must first receive a molecular “tag” that directs them to the lysosome. In individuals with ML II and ML III, this tag is not properly attached because of a deficiency in the enzyme phospho-N-acetylglucosamine transferase. As a result, the enzymes are unable to reach the lysosome, leading to the buildup of cellular material. Cells affected in this way are called “inclusion cells,” which is why ML II is also known as I-Cell disease. Symptoms typically become apparent over time as cellular damage progresses.

 

ML II (I-Cell disease) and ML III (Pseudo-Hurler syndrome) are inherited in an autosomal recessive pattern. When both parents are carriers, each pregnancy carries a 25% chance that the child will inherit both altered genes and be affected by the condition. Unaffected siblings may also be carriers.

​

While ML II and ML III present significant medical challenges, ongoing research continues to improve understanding of these disorders and advance the development of potential therapies. Increased awareness, early diagnosis, supportive care, and continued scientific collaboration remain important in improving outcomes and quality of life for affected individuals and their families.